Intelligent Network Concepts, Inc.
Wednesday, February 25, 1998
* A recent report suggests that there is a small risk of bone
marrow transplant recipients developing diabetes after
receiving bone marrow from diabetic donors.
- European researchers reviewed data from 17,000 bone marrow
transplant cases to collect data after findings one case
in which diabetes was apparently transferred from a
donor to a recipient.
- authors concluded that there is a real risk of transferring
diabetes from bone marrow donors to recipients, but
suggest that the risk is so small as to not warrant
the exclusion of an otherwise eligible donor simply
because they have diabetes.
- the report is in The Lancet (1998;351:568-569).
DRUGS, PRODUCTS, AND POLICY
* Researchers have reported the development of a drug which
aids in the evaluation of a tumor's oxygen content, a
measure which will enable treatments to be better fine-
tuned to individuals.
- researchers at the University of Pennsylvania Cancer Center
say the drug, EF5, binds to tumor cells which thrive
in oxygen-deprived environments (hypoxic), which are
known to be more resistant to radiation and chemotherapy
treatment that other cancer cells.
- authors say the drug has recently been approved for
Phase I clinical trials by the FDA and that it is
hoped that the drug can be adapted for use with
Positron Emission Tomography (PET) imaging.
- data taken from a University of Pennsylvania Cancer Center
release (February 24, 1998).